Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Diagnosis & Disease Information
Asciminib Shows Early Promise as Frontline Therapy for CML-CP
Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.
Tyrosine Kinase Inhibitor Discontinuation Safe in Pediatric Chronic Myeloid Leukemia
Researchers sought to determine if discontinuation of TKI therapy was safe for pediatric patients with CML.
Illegitimate Online Pharmacies May Put Cancer Patients at Risk
Illegitimate online pharmacies are selling imatinib without a prescription, making false claims about being registered with regulatory bodies, and failing to provide patients with drug-related warnings.
Asciminib Continues to Demonstrate Superior Efficacy for CML-CP
The patients were randomly assigned 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily.
Longer Deep Molecular Remission in CML Associated With Treatment-Free Remission
The investigators performed univariate and multivariate analyses to identify factors associated with the loss of MMR.
Use of Oral Tyrosine Kinase Inhibitors for R/R CML Increasing Over Time
From 2017 to 2019, the number of beneficiaries prescribed at least 1 oral TKI increased from 154 beneficiaries to 212 beneficiaries.
CML Does Not Affect Antibody Development Against SARS-CoV-2
Investigators reported findings from the ongoing SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) study.
Trends in Second Malignancy and Mortality Risk After Primary Chronic Myeloid Leukemia
In CML, second malignancies are rare and trends remain poorly understood.
Guidelines for CML Not Followed in the Real World
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
- Loading...
Loading...
Next post in EHA 2022
Loading... 
Loading...